• Publications
  • Influence
Diagnosis, management, and treatment of hepatitis C: An update
This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
  • 2,923
  • 179
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV). These drugs are administered forExpand
  • 1,087
  • 38
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study.
BACKGROUND/AIMS It is unclear whether tumor location, size, or the presence of multiple endocrine neoplasia type 1 (MEN-1) alters metastatic rate and survival in patients with pancreatic endocrineExpand
  • 426
  • 18
National Institutes of Health consensus development conference statement: Management of hepatitis B
Hepatitis B is a major cause of liver disease worldwide, ranking as a substantial cause of cirrhosis and hepatocellular carcinoma. The development and use of a vaccine for hepatitis B virus (HBV) hasExpand
  • 269
  • 10
Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection
BACKGROUND:Many veterans may not be candidates for hepatitis C virus (HCV) treatment due to contraindications to therapy. The aims of this study were to determine the proportion of HCV-infectedExpand
  • 155
  • 6
Use of complementary and alternative medicine in patients with liver disease
OBJECTIVES:Complementary and alternative medicine (CAM) is used by 42% of the U.S. population. Its use among patients with chronic liver disease has not been well defined. Toward that end, weExpand
  • 156
  • 5
Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection.
BACKGROUND Tests for hepatitis C antibodies (anti-HCV enzyme immunoassays) are usually described as positive or negative. Several studies, mainly in blood donors, have found that specimens with lowExpand
  • 82
  • 5
Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I.
PURPOSE To determine whether patients with multiple endocrine neoplasia type I (MEN-I) can initially present with Zollinger-Ellison syndrome (ZES), and to learn whether ZES exhibits anyExpand
  • 110
  • 3
Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans.
Paraoxonase 1 (PON) may contribute to the cardioprotective action of high-density lipoprotein (HDL) because it inhibits low-density lipoprotein (LDL) oxidation, a prerequisite for the onset ofExpand
  • 98
  • 3
The natural history of chronic hepatitis C infection.
Hepatitis C is among the most common causes of chronic liver disease affecting approximately 1% of the world's population. End-stage hepatitis C virus (HCV)-related chronic liver disease is theExpand
  • 55
  • 1